Introduction
Angiogenesis is a pivotal event in prostate cancer (CaP) progression, facilitating the growth and metastasis of this tumor. Critical to this process is the ability for tumor cells to secrete angiogenic cytokines, an initiating step in vascular hyperpermeability, protease secretion, capillary basement membrane breakdown, and endothelial cell migration and proliferation. 1 ± 3 In many tumor systems, the impetus for angiogenesis studies stems from observations regarding angiogenic cytokine expression by established cell lines. Human CaP established cell lines potentially express several recognized cytokines involved in angiogenesis, including basic ®broblast growth factor (bFGF), vascular endothelial growth factor/vascular permeability factor (VEGF), tumor necrosis factor alpha (TNF-a), and urokinase-type plasminogen activator (u-PA).
Vascular endothelial growth factor (VEGF) has been shown to affect the proliferation, migration, and vascular permeability of endothelial cells and is an inducer of in vitro angiogenesis. 4 ± 9 Neutralizing anti-VEGF antibodies have been shown in vivo to inhibit the growth of several cancers and to reduce tumor blood vessel density. 10 Immunohistochemical (IHC) studies of VEGF in CaP have varied. One study shows increased expression of VEGF in CaP specimens, but not in normal or BPH specimens, 11 while another reports widespread distribution of VEGF staining in CaP and BPH specimens. 12 bFGF is also a pro-angiogenic molecule and will induce endothelial cell proliferation, migration, and protease expression. 4,8,13 ± 15 Anti-bFGF antibodies have been shown to inhibit cell growth and tumor formation of human glioblastoma cells in nude mice. 16 Higher levels of bFGF protein have been demonstrated in whole tumor extracts of prostate cancer than in extracts of uninvolved prostate peripheral zone tissue. 17 bFGF expression in endothelial cells is up-regulated by human hepatoma or mouse sarcoma conditioned medium, and bFGF in turn increases u-PA production and cell motility. 18 TNF-a is pro-apoptotic to prostate epithelium, but it is also a strong inducer of proteolytic cytokine expression by human endothelial cells and is angioenic in vivo. 19, 20 While the balance between these two different functions has not been elucidated, its expression by established cell lines and primary CaP cultures has not been compared. VEGF, bFGF and TNF-a when added in combination to human endothelial cells induce tube formation in in vitro angiogenesis assays to a greater extent than when added alone or in paired combination. 21 u-PA is a serine protease that cleaves the proenzyme plasminogen to form plasmin. Plasmin in turn is a broad spectrum protease with the ability to degrade components of extracellular matrix. It is hypothesized that u-PA expression by cancer cells plays a direct role in the invasion of cells into the local environment for metastasis. Elevated levels of u-PA have been found in in vitro CaP cell lines with high metastatic potential. 22, 23 By IHC, u-PA expression has been found to be increased in cancer specimens with extracapsular extension vs specimens without extracapsular extension. 24 Endothelial cells also secrete u-PA, and this facilitates their ability to degrade tumor matrix and establish neovascularization. 25 Expression of a mutant, proteolytically inactive form of u-PA is shown to signi®cantly decrease CaP tumor growth and angiogenesis in vivo. 26 We hypothesized, that established CaP cell line cultures growing in monolayer and lacking stromal support would not secrete the same cytokine pro®le as is found in epithelial and stromal primary cultures derived from surgical CaP specimens. Our results support this hypothesis, demonstrating differences in the two environments.
Methods
Established CaP cell lines: LNCaP, PC3, and their orthotopic selected sublines from primary prostate growth and lymph node metastasis were a generous gift from Dr Curtis Pettaway. 27 PC3M cells are from a liver metastasis of PC3 cells injected under the splenic capsule. LNCaPPro5 and PC3-Pro4 cells are derived from orthotopic growth following intra-prostatic injection of their respective parental cell types. LNCaP-LN3 and PC3-LN4 cells are derived from lymph node metastasis following orthotopic injection of their respective parental cell lines. Cell lines were maintained in RPMI 1640 containing 10% fetal bovine serum, penicillin 100 U/ml, and streptomycin 100 mg/ml. When 75% con¯uent, cell cultures were washed twice with PBS and serum-free medium was added for a 24 h period. CM was ®ltered and stored at 740 C. Mirror image adjacent sections were taken for paraf®n embedding and histological analysis. All samples were washed in DBSS, minced into 1 mm pieces with a scalpel and centrifuged at 3500 RPM for 5 min. Samples were resuspended in PrEGM (Clonetics, San Diego) containing 10 ng/ml collagenase (Sigma, St Louis) and incubated on a rotary shaker at 37 C overnight. The next day, samples were centrifuged, washed twice in DBSS, and placed into 60 mm tissue culture plates containing MCDB 104 which contained 10% fetal bovine serum, penicillin 100 U/ml, and streptomycin 100 mg/ml or PrEGM containing 10 ng/ml cholera toxin (Sigma, St Louis) and incubated at 37 C, 5% CO 2 MCDB 104 selects for prostate stromal cell growth and PrEGM for epithelial cell growth. Cultures were passaged twice before 24 h serum and growth factor free conditioned media (CM) was collected.
Representative epithelial and stromal cultures underwent IHC with antibodies against actin, pan-cytokeratin, AE1/AE3 and vimentin to verify the purity of their respective cell populations.
ELISAs
CM was assayed for bFGF, VEGF and TNF-a by their respective ELISAs (Quantikine, R&D Systems, Minneapolis) and performed according to the manufacturer's protocols.
Urokinase quantitation
Twenty-four hour CM was thawed and assayed for u-PA by ELISA utilizing a quantitative sandwich immunoassay. Ninety-six well plates were coated with anti-urokinase antibody 4D1E8 (provided by Dr Desire Collen, Leuven, Belgium) and blocked with 1% bovine serum albumin. Consecutive dilutions of recombinant single chain urokinase were used to generate a standard curve for the assay. Diluted CM (180 ml) was added to each well and the plate was incubated at 37 C for 2.5 h. Wells were washed with PBS/0.01% Tween-80 and incubated with 170 ml of horseradish peroxidase conjugated urokinase antibody against a different epitope (Dr Desire Collen, Leuven Belgium) at 1 : 2000 dilution at 37
C for 1 h. All wells were again washed and incubated with 150 ml of ABTS solution (Roche, Basel, Switzerland) for 30 min. u-PA levels were quatitated by spectrophotometric analysis at 410 nm on an ELISA plate reader.
Northern blotting
Total cellular RNA was collected from sub-con¯uent cultures in P100 tissue culture¯asks utilizing trizol reagent (Gibco BRL, Gaitherburg). RNA (20 mg) was run on 1% formaldehyde agarose gel and transferred to a positively charged nylon membrane (Hybond-N, Amersham Pharmacia, Piscataway). The blot was pre-hybridized for 45 min at 65 C and then hybridized for 14 h at 65 C with¯uoresceine labelled u-PA probe. After hybridization the blot was washed twice in SSC/SDS at 65 C for 15 min each wash and blocked in liquid block for 1 h. Anti-¯ourescein antibody (Amersham Pharmacia, Piscataway) at 1 : 5000 dilution was added for 1 h. Probe detection was performed using CDP-Star detection reagent (Amersham Pharmacia, Piscataway) and exposed to autoradiographic ®lm for 3 h.
Western blotting
Near con¯uent cells were incubated in serum-free and growth factor-free media for 24 h. Media was collected, centrifuged, and frozen at 740 C until analyzed. CM containing equal amounts of protein was directly loaded in 10.5% SDS polyacrylamide gel and then electrophoresed under non-reducing conditions and transferred to nitrocellulose. The blot was incubated in 5% milk for 1 h in PBS and incubated with anti-urokinase antibody #389 (American Diagnostica, Greenwich) overnight at 4 C. After incubation, the membrane was exposed to horseradish peroxidase conjugated rabbit anti-mouse antibody (Sigma, St Louis) for 1 h and complexes were detected by enhanced chemiluminescence and exposed to autoradiographic ®lm for 5 min.
Statistics
ELISA samples were run in duplicate and experiments repeated three times. Values shown are the mean, and standard error in the triplicate experiments was found to be`10% of the mean. Comparisons were made by ranksum analysis.
Results

CaP specimens from radical retropubic prostatectomy
Only specimens with histological mirror image con®rma-tion of CaP were included. All CaP samples came from palpable and visible abnormalities in the peripheral zone. Eighteen patients made up the core sample size, with 11 having Gleason scores ! 7 (Gleason 7 n 7; Gleason 8 n 2; Gleason 9 n 1; Gleason 10 n 1). Seven patients had Gleason 6 (Gleason 5 n 1; Gleason 6 n 6).
Expression of basic ®broblast growth factor
bFGF was not detected in CM from the PC3 nor the LNCaP cell lines (data not shown). This is consistent with reports that bFGF is variably secreted by different cell types, as all bFGF mRNA translational products lack a secretory leader signal sequence and most cells do not have a carrier protein. 15, 28 Eighteen primary CaP stromal cultures were assessed for bFGF secretion in their CM by ELISA. The cultured stromal specimens expressed a mean of 51.3 AE 11 pg/mg protein. A comparison of bFGF expression by Gleason score 6 or ! 7 is shown in Table 1 , and did not differ with statistical signi®cance. We did not detect the secretion of bFGF in primary CaP epithelial cultures, which is consistent with our established cell lines (Table 1) .
Expression of vascular endothelial growth factor
LNCaP and PC3 cell lines and their subtypes all secrete signi®cant VEGF; however, the LNCaP lines demonstrated the highest levels ( Figure 1) 
Expression of tumor necrosis factor-a
We were unable to detect TNF-a in the CM from any of the cell lines and primary CaP cell cultures examined (data not shown).
Expression of urokinase type plasminogen activator u-PA expression was compared in PC3 and LNCaP parental cells and their sublines. u-PA mRNA expression in the parental sublines and Figure 3 Basic ®broblast growth factor has been shown to have important angiogenic effects in cancer. 4, 8, 13, 22, 28, 33 bFGF stimulates endothelial cell proliferation and u-PA expression. 14 This facilitates matrix proteolysis for endothelial cell migration and neovascularization. 14 We found increased levels of bFGF expression from the stromal, but not epithelial component of CaP primary culture specimens. Established CaP cell lines did not secrete bFGF, consistent with the need for a hydrophobic carrier protein to transport bFGF into the extracellular environment. Joseph and Isaacs however, have reported a small amount of bFGF secreted into the CM by PC3 cells using a similar ELISA test. 34 In vivo the supporting stroma is likely to be an important paracrine source of bFGF in human CaP. This would not be appreciated in studies limited to established cell lines.
VEGF is expressed by all of the established CaP cell lines we studied. VEGF is also reportedly secreted from DU-145 human CaP cells, and others report lesser expression from LNCaP, PC3 and TSU-PRI cells. 11, 34 Balbay and associates measured VEGF in LNCaP cells and the same two orthotopically derived sublines which we studied; LNCaP-LN3 and LNCaP-Pro5. They found VEGF expressed to a greater extent by the LNCaP-LN3 metastatic variant in vitro. 35 Similar relative expression was also noted when these cell lines were grown orthotopically in mice, with LNCaP-LN3 secretion greater than LNCaP or LNCaP-Pro5. 35 We found that both the stromal and epithelial components of CaP primary culture specimens express VEGF. The epithelial cultures secrete approximately 10 times more VEGF than the stromal cultures, although the stroma produces a considerable amount. Our observation that tumor associated stroma secretes both bFGF and VEGF in human CaP cultures, has not, to our knowledge been previously reported. bFGF and VEGF overexpression by CaP stroma may play an important role in the pathogenesis of this disease, in¯u-encing the biological behavior and function of endothelial cells.
We were unable to detect TNF-a in the CM from the established CaP cell lines nor the primary epithelial and stromal cultures. TNF-a strongly upregulates u-PA expression by endothelial cells making it very pro-angiogenic, as shown in Figure 3 . 20 This was the rationale for studying it. Interestingly, in other work, we have detected TNF-a in the epithelial cells of BPH and CaP by immunohistochemistry using a monoclonal antibody against TNF-a (submitted, data not shown). The staining intensity was greater in the CaP glands. Tumor in®ltrating macrophages, which can also produce TNF-a are not detected in the tissue sections studied, and are not the source of the TNF-a. These data suggest that TNF-a may be a contributor to angiogenesis in CaP, but that epithelial cells are not expressing this cytokine following digestion and monolayer growth in culture. TNF-a is noted to induce apoptosis in CaP, and the balance between angiogenesis and apoptosis has not been de®ned.
u-PA contributes to the growth, invasion, and progression of CaP. 36 We have con®rmed the observation by Hollas and associates 23 that LNCaP cell lines do not express u-PA while PC3 lines express high levels of the protease. In other work we have shown that u-PA expression is repressed in androgen sensitive CaP by mechanisms involving the androgen receptor, and upregulated via mitogen activated protein kinase signaling pathway (submitted). To verify that the absence of u-PA expression by LNCaP cells was not due to a post translational event, u-PA Northern blotting was performed (Figure 2) . The major source of u-PA in our primary cultures was epithelial in origin. All primary cultures were derived from patients who had never undergone androgen deprivation. Our results therefore indicate that androgen sensitive CaP cells express u-PA, a ®nding not re¯ected by established cell lines. We have previously reported that expression of a mutant form of u-PA from highly metastatic CaP cells, which is receptor binding competent but proteolytically inactive decreases primary CaP growth, angiogenesis and metastasis in vivo. 26 This is likely because in a homologous model, the endothelial cell u-PA receptor is bound with mutant u-PA. These data suggest that both tumor and endothelial u-PA expression are important for angiogenesis.
Angiogenesis is a multifactorial process in¯uenced by selective expression of cytokines from both epithelial and stromal components. In this study we have shown that the expression of bFGF, VEGF, and u-PA by established CaP cell lines is not completely re¯ective of primary culture expression. Interestingly, there was no statistical difference in cytokine expression by tumors with Gleason score's 6 vs ! 7. While this was initially surprising, our ongoing work is demonstrating that BPH and CaP from the same prostates have similar angiogenic cytokine expression pro®les (data in preparation). These observations have therapeutic implications, as the primary culture data may provide direction in selecting angiogenesis inhibitors. For example, bFGF which was expressed by primary culture stroma, but not established cell lines can have a paracrine effect stimulating endothelial cell proliferation and migration. In other work we are investigating this relationship and mechanisms to inhibit it. We feel these data are important observations in clarifying angiogenic cytokine production in CaP.
